Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses

Abstract

Receptor tyrosine kinases (RTKs) bearing oncogenic mutations in EGFR, ALK and ROS1 occur in a significant subset of lung adenocarcinomas. Tyrosine kinase inhibitors (TKIs) targeting tumor cells dependent on these oncogenic RTKs yield tumor shrinkage, but also a variety of adverse events. Skin toxicities, hematological deficiencies, nausea, vomiting, diarrhea, and headache are among the most common, with more acute and often fatal side effects such as liver failure and interstitial lung disease occurring less frequently. In normal epithelia, RTKs regulate tissue homeostasis. For example, EGFR maintains keratinocyte homeostasis while MET regulates processes associated with tissue remodeling. Previous studies suggest that the acneiform rash occurring in response to EGFR inhibition is a part of an inflammatory response driven by pronounced cytokine and chemokine release and recruitment of distinct immune cell populations. Mechanistically, blockade of EGFR causes a Type I interferon response within keratinocytes and in carcinoma cells driven by this RTK. This innate immune response within the tumor microenvironment (TME) involves increased antigen presentation and effector T cell recruitment that may participate in therapy response. This TKI-mediated release of inflammatory suppression represents a novel tumor cell vulnerability that may be exploited by combining TKIs with immune-oncology agents that rely on T-cell inflammation for efficacy. However, early clinical data indicate that combination therapies enhance the frequency and magnitude of the more acute adverse events, especially pneumonitis, hepatitis, and pulmonary fibrosis. Further preclinical studies to understand TKI mediated inflammation and crosstalk between normal epithelial cells, cancer cells, and the TME are necessary to improve treatment regimens for patients with RTK-driven carcinomas.

Keywords

Tyrosine kinase inhibitor / receptor tyrosine kinase / interferon / inflammation / tumor microenvironment / epithelial tissue homeostasis

References

[1] Siegel RL,Jemal A.Cancer statistics, 2018.CA Cancer J Clin2018;68:7-30

[2] Politi K.Lung cancer in the era of precision medicine.Clin Cancer Res2015;21:2213-20 PMCID:PMC4505624

[3] Vermorken JB,Rivera F,Kawecki A,Erfan J,Kienzer HR,Peyrade F,Vynnychenko I,Bokemeyer C,Amellal N.Platinum-based chemotherapy plus cetuximab in head and neck cancer.N Engl J Med2008;359:1116-27

[4] Camidge DR,Sequist LV.Acquired resistance to TKIs in solid tumours: learning from lung cancer.Nat Rev Clin Oncol2014;11:473-81

[5] Dy GK.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.CA Cancer J Clin2013;63:249-79

[6] Shaw AT,Nakagawa K,Crinó L,De Pas T,Solomon BJ,Wu YL,O'Byrne KJ,Camidge DR,Hirsh V,Iyer S,Polli A,Jänne PA.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med2013;368:2385-94

[7] Camidge DR,Kwak EL,Varella-Garcia M,Riely GJ,Ou SH,Salgia R,Engelman JA,Jänne PA,Shapiro GI,Ruffner K,Tang Y,Clark JW.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol2012;13:1011-9

[8] van Geel RM,Vahl JE,van den Broek D,Beijnen JH,Burgers SA.Crizotinib-induced fatal fulminant liver failure.Lung Cancer2016;93:17-9

[9] Liu B,Sun Y,Zhang Z,Wang X.Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.Oncotarget2018;9:9480-8

[10] Costa RB,Talamantes SM,Bhave MA,Miller C,Mahalingam D.Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.Oncotarget2018;9:22137-46 PMCID:PMC5955140

[11] Roskoski R.The ErbB/HER family of protein-tyrosine kinases and cancer.Pharmacol Res2014;79:34-74

[12] Lichtenberger BM,Holcmann M,Amberg N,Schrumpf H,Ansari P,Wollenberg A,Fischer JW,Harder J,Homey B.Epidermal EGFR controls cutaneous host defense and prevents inflammation.Sci Transl Med2013;5:199ra11

[13] Mascia F,Keith C,Steinberg SM,Yuspa SH.Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.Sci Transl Med2013;5:199ra110

[14] Sibilia M,Lichtenberger BM,Hecking M.The epidermal growth factor receptor: from development to tumorigenesis.Differentiation2007;75:770-87

[15] Suzuki H,Yokohori N.Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.Cancer Res2003;63:5054-9

[16] Sakao S.Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors.Oncol Lett2012;4:865-7 PMCID:PMC3499618

[17] Trusolino L,Comoglio PM.MET signalling: principles and functions in development, organ regeneration and cancer.Nat Rev Mol Cell Biol2010;11:834-48

[18] Borowiak M,Wüstefeld T,Trautwein C.Met provides essential signals for liver regeneration.Proc Natl Acad Sci U S A2004;101:10608-13 PMCID:PMC490025

[19] Kroy DC,Ramadori P,Bergheim I,Boekschoten MV,Streetz KL.Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice.J Hepatol2014;61:883-90

[20] Brinkmann V,Sachs M,Birchmeier W.Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells.J Cell Biol1995;131:1573-86

[21] Agero AL,Benvenuto-Andrade C,Myskowski P.Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.J Am Acad Dermatol2006;55:657-70

[22] Bonner JA,Giralt J,Shin DM,Jones CU,Raben D,Ove R,Baselga J,Amellal N,Ang KK.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N Engl J Med2006;354:567-78

[23] Liu HB,Lv TF,Xiao YY,Song Y.Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.PLoS One2013;8:e55128 PMCID:PMC3559430

[24] Mohamed MK,Lin Y,Belani CP.Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.Ann Oncol2005;16:780-5

[25] Petrelli F,Cabiddu M,Barni S.Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.Lung Cancer2012;78:8-15

[26] Pastore S,Girolomoni G.Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.Arch Toxicol2014;88:1189-203

[27] Mascia F,Girolomoni G.Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation.Am J Pathol2003;163:303-12

[28] Ivashkiv LB.Regulation of type I interferon responses.Nat Rev Immunol2014;14:36-49 PMCID:PMC4084561

[29] Pollack BP,Cartee TV.Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.Clin Cancer Res2011;17:4400-13

[30] Kersh AE,Cooper LA,Pollack BP.Understanding the impact of ErbB activating events and signal transduction on antigen processing and presentation: MHC expression as a model.Front Pharmacol2016;7:327 PMCID:PMC5052536

[31] Pollack BP.EGFR inhibitors, MHC expression and immune responses: can EGFR inhibitors be used as immune response modifiers?.Oncoimmunology2012;1:71-4 PMCID:PMC3376950

[32] Kumai T,Oikawa K,Kimura S,Celis E.EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.Br J Cancer2013;109:2155-66 PMCID:PMC3798972

[33] Kumai T,Nagato T,Oikawa K,Kimura S,Harabuchi Y.Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma.Sci Rep2015;5:16280 PMCID:PMC4633732

[34] Natalia J.Gurule NJ, McCoach C, Hinz TK, Marek L, Ryall K, Korpela S, Sisler D, Tan AC, Doebele RC, Heasley LE. Oncogene-targeted agents induce and interferon response in EGFR and EML4-ALK driven lung cancer. In: Cancer Immunotherapy Combinations2018;Montreal, CanadaKeystone Symposia

[35] Borghaei H,Horn L,Steins M,Chow LQ,Felip E,Barlesi F,Arrieta O,Fayette J,Poddubskaya E,Gettinger SN,Rizvi N,Blumenschein GRJr,Dorange C,Graf Finckenstein F.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med2015;373:1627-39 PMCID:PMC5705936

[36] Gajewski TF,Williams J,Sivan A.Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment.Adv Exp Med Biol2017;1036:19-31

[37] Spranger S.Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.Int Immunol2016;28:383-91 PMCID:PMC4986232

[38] Spranger S.Tumor-intrinsic oncogene pathways mediating immune avoidance.Oncoimmunology2015;5:e1086862 PMCID:PMC4839364

[39] Ayers M,Nebozhyn M,Loboda A,Albright A,Kang SP,Piha-Paul SA,Seiwert TY,McClanahan TK.IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade.J Clin Invest2017;127:2930-40 PMCID:PMC5531419

[40] Moya-Horno I,Karachaliou N.Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).Ther Adv Med Oncol2018;10:1758834017745012 PMCID:PMC5784559

[41] Ahn MJ,Saka H,Goto K,Yang L,Oxnard GR.136O - Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial.J Thorac Oncol2016;

[42] Rizvi NA,Borghaei H,Harbison C,Chen AC.Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).J Clin Oncol2014;32:8022

[43] Oshima Y,Yuji K.EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer.JAMA Oncol2018;4:1112-5

[44] Spigel DR,Waterhouse D,Chandler J,Thurmes P,Jotte R,Lin WH.Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370).J Thorac Oncol2018;13:682-8

[45] Harvey CE,Palladinetti P,Ffrench RA,Marinos G.Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation.J Leukoc Biol2003;74:360-9

[46] Pechkovsky DV,Ludwig C,Vollmer E,Zissel G.CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II.Respir Res2005;6:75 PMCID:PMC1185567

[47] Harada C,Ogata-Suetsugu S,Hamada N,Souzaki R,Taguchi T,Nakanishi Y.EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium.Am J Respir Crit Care Med2011;183:743-51

[48] Mikumo H,Hamada N,Ogata-Suetsugu S,Arimura-Omori M,Yokoyama T.Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice.Biochem Biophys Res Commun2017;486:205-9